Genmab's Potential Leukemia Treatment Shows Overall Response Rate of 61% in Phase 1/2 Trial

MT Newswires Live12-09

Genmab (GMAB) said Sunday that results from a phase 1/2 clinical trial of epcoritamab showed an overall response rate of 61% and a complete response rate of 39% in difficult-to-treat adult patients with relapsed or refractory chronic lymphocytic leukemia.

Among all patients treated with the subcutaneously administered T-cell engaging antibody, median progression-free survival was 12.8 months and an estimated 65% were alive at 15 months, the Danish pharmaceutical company said.

Side effects of the treatment included cytokine release syndrome, diarrhea, edema, fatigue, and injection-site reaction, the company said.

Chronic lymphocytic leukemia is the most common leukemia.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2490554743?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-09 16:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2490554743","market":"sh","top_or_hot":-1,"title":"Genmab's Potential Leukemia Treatment Shows Overall Response Rate of 61% in Phase 1/2 Trial","media":"MT Newswires Live","content":"<html><body><p> Genmab (GMAB) said Sunday that results from a phase 1/2 clinical trial of epcoritamab showed an overall response rate of 61% and a complete response rate of 39% in difficult-to-treat adult patients with relapsed or refractory chronic lymphocytic leukemia.</p><p>Among all patients treated with the subcutaneously administered T-cell engaging antibody, median progression-free survival was 12.8 months and an estimated 65% were alive at 15 months, the Danish pharmaceutical company said.</p><p>Side effects of the treatment included cytokine release syndrome, diarrhea, edema, fatigue, and injection-site reaction, the company said.</p><p>Chronic lymphocytic leukemia is the most common leukemia.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genmab's Potential Leukemia Treatment Shows Overall Response Rate of 61% in Phase 1/2 Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenmab's Potential Leukemia Treatment Shows Overall Response Rate of 61% in Phase 1/2 Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-12-09 16:47 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Genmab (GMAB) said Sunday that results from a phase 1/2 clinical trial of epcoritamab showed an overall response rate of 61% and a complete response rate of 39% in difficult-to-treat adult patients ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2490554743","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2490554743","pubTimestamp":1733734059,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Genmab  said Sunday that results from a phase 1/2 clinical trial of epcoritamab showed an overall response rate of 61% and a complete response rate of 39% in difficult-to-treat adult patients with relapsed or refractory chronic lymphocytic leukemia.Among all patients treated with the subcutaneously administered T-cell engaging antibody, median progression-free survival was 12.8 months and an estimated 65% were alive at 15 months, the Danish pharmaceutical company said.Side effects of the treatment included cytokine release syndrome, diarrhea, edema, fatigue, and injection-site reaction, the company said.Chronic lymphocytic leukemia is the most common leukemia.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","GMAB":"Genmab A/S"},"translate_title":"Genmab潜在白血病疗法1/2期试验总体缓解率达61%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GMAB":0.9},"content_text":"Genmab (GMAB) said Sunday that results from a phase 1/2 clinical trial of epcoritamab showed an overall response rate of 61% and a complete response rate of 39% in difficult-to-treat adult patients with relapsed or refractory chronic lymphocytic leukemia.Among all patients treated with the subcutaneously administered T-cell engaging antibody, median progression-free survival was 12.8 months and an estimated 65% were alive at 15 months, the Danish pharmaceutical company said.Side effects of the treatment included cytokine release syndrome, diarrhea, edema, fatigue, and injection-site reaction, the company said.Chronic lymphocytic leukemia is the most common leukemia.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2490554743"}